Journal Article
. 2008 Jan;10(1).
doi: 10.1186/bcr1847.

Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study

Simon J Crabb 1 Chris D Bajdik  Samuel Leung  Caroline H Speers  Hagen Kennecke  David G Huntsman  Karen A Gelmon  
  • PMID: 18194560
  •     34 References
  •     14 citations


Introduction: Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups.

Methods: Patients with four or more positive axillary nodes were identified from a clinically annotated tissue microarray of formalin-fixed paraffin-embedded primary breast cancers and randomized into a 'test set' and a 'validation set'. A prospectively defined prognostic scoring model was developed in the test set and was further assessed in the validation set combining expression for eight biomarkers by immunohistochemistry, including estrogen receptor, human epidermal growth factor receptors 1 and 2, carbonic anhydrase IX, cytokeratin 5/6, progesterone receptor, p53 and Ki-67. Survival outcomes were analyzed by the Kaplan-Meier method, log rank tests and Cox proportional-hazards models.

Results: A total of 313 eligible patients were identified in the test set for whom 10-year relapse-free survival was 38.3% (SEM 2.9%), with complete immunohistochemical data available for 227. Tumor size, percentage of positive axillary nodes and expression status for the progesterone receptor, Ki-67 and carbonic anhydrase IX demonstrated independent prognostic significance with respect to relapse-free survival. Our combined biomarker scoring system defined three subgroups in the test set with mean 10-year relapse-free survivals of 75.4% (SEM 7.0%), 35.3% (SEM 4.1%) and 19.3% (SEM 7.0%). In the validation set, differences in relapse-free survival for these subgroups remained statistically significant but less marked.

Conclusion: Biomarkers assessed here carry independent prognostic value for breast cancer with four or more positive axillary nodes and identified clinically relevant prognostic subgroups. This approach requires refinement and validation of methodology.

What do we mean by validating a prognostic model?
D G Altman, P Royston.
Stat Med, 2000 Mar 01; 19(4). PMID: 10694730
Highly Cited.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
P Eifel, J A Axelson, +11 authors, D Roter.
J Natl Cancer Inst, 2001 Jul 05; 93(13). PMID: 11438563
Highly Cited. Review.
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.
S K Chia, C C Wykoff, +6 authors, A L Harris.
J Clin Oncol, 2001 Aug 16; 19(16). PMID: 11504747
Highly Cited.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Revision of the American Joint Committee on Cancer staging system for breast cancer.
S Eva Singletary, Craig Allred, +17 authors, Frederick L Greene.
J Clin Oncol, 2002 Aug 31; 20(17). PMID: 12202663
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.
Nikita A Makretsov, David G Huntsman, +8 authors, C Blake Gilks.
Clin Cancer Res, 2004 Sep 28; 10(18 Pt 1). PMID: 15448001
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.
C L Carter, C Allen, D E Henson.
Cancer, 1989 Jan 01; 63(1). PMID: 2910416
Highly Cited.
Compliance with practice guidelines for node-negative breast cancer.
A Olivotto, A J Coldman, +4 authors, C Sawka.
J Clin Oncol, 1997 Jan 01; 15(1). PMID: 8996145
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Nuclear beta-catenin in mesenchymal tumors.
Tony L Ng, Allen M Gown, +6 authors, Torsten O Nielsen.
Mod Pathol, 2004 Sep 18; 18(1). PMID: 15375433
Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays.
Grace Callagy, Paul Pharoah, +4 authors, Carlos Caldas.
J Pathol, 2005 Feb 01; 205(3). PMID: 15682439
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis.
Jocelyne Jacquemier, Christophe Ginestier, +11 authors, François Bertucci.
Cancer Res, 2005 Feb 12; 65(3). PMID: 15705873
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
Pauline T Truong, Eric Berthelet, +2 authors, Ivo A Olivotto.
Cancer, 2005 Apr 07; 103(10). PMID: 15812825
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.
Dalia M Abd El-Rehim, Graham Ball, +6 authors, Ian O Ellis.
Int J Cancer, 2005 Apr 09; 116(3). PMID: 15818618
Highly Cited.
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A Goldhirsch, J H Glick, +4 authors, Panel members.
Ann Oncol, 2005 Sep 09; 16(10). PMID: 16148022
Highly Cited.
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
Melody A Cobleigh, Bita Tabesh, +7 authors, Steven Shak.
Clin Cancer Res, 2005 Dec 20; 11(24 Pt 1). PMID: 16361546
The impact of expression profiling on prognostic and predictive testing in breast cancer.
J S Reis-Filho, C Westbury, J-Y Pierga.
J Clin Pathol, 2006 Mar 01; 59(3). PMID: 16505270    Free PMC article.
High-throughput techniques in breast cancer: a clinical perspective.
Enrique Espinosa, Andrés Redondo, +4 authors, Manuel González Barón.
Eur J Cancer, 2006 Jan 25; 42(5). PMID: 16431104
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.
Grace M Callagy, Paul D Pharoah, +6 authors, Carlos Caldas.
Clin Cancer Res, 2006 Apr 28; 12(8). PMID: 16638854
The molecular portraits of breast tumors are conserved across microarray platforms.
Zhiyuan Hu, Cheng Fan, +28 authors, Charles M Perou.
BMC Genomics, 2006 Apr 29; 7. PMID: 16643655    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Concordance among gene-expression-based predictors for breast cancer.
Cheng Fan, Daniel S Oh, +5 authors, Charles M Perou.
N Engl J Med, 2006 Aug 11; 355(6). PMID: 16899776
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
Jan Bogaerts, Fatima Cardoso, +12 authors, TRANSBIG consortium.
Nat Clin Pract Oncol, 2006 Oct 05; 3(10). PMID: 17019432
Classification of breast cancer using genetic algorithms and tissue microarrays.
Marisa Dolled-Filhart, Lisa Rydén, +4 authors, David L Rimm.
Clin Cancer Res, 2006 Nov 07; 12(21). PMID: 17085660
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.
S A Hussain, R Ganesan, +12 authors, D H Palmer.
Br J Cancer, 2007 Jan 11; 96(1). PMID: 17213826    Free PMC article.
Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.
S-F Chin, Y Wang, +15 authors, C Caldas.
Oncogene, 2006 Sep 27; 26(13). PMID: 17001317
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Sherene Loi, Benjamin Haibe-Kains, +14 authors, Christos Sotiriou.
J Clin Oncol, 2007 Apr 03; 25(10). PMID: 17401012
Highly Cited.
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.
Ashish B Rajput, Dmitry A Turbin, +5 authors, David G Huntsman.
Breast Cancer Res Treat, 2007 Apr 14; 107(2). PMID: 17431762    Free PMC article.
Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'.
Donal J Brennan, William M Gallagher.
Breast Cancer Res, 2008 Mar 12; 10(1). PMID: 18331621    Free PMC article.
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
Elton Rexhepaj, Donal J Brennan, +6 authors, William M Gallagher.
Breast Cancer Res, 2008 Oct 25; 10(5). PMID: 18947395    Free PMC article.
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.
Donal J Brennan, Darran P O'Connor, +2 authors, William M Gallagher.
Nat Rev Cancer, 2010 Aug 20; 10(9). PMID: 20720569
Extending the tissue microarray data exchange specification for inclusion of data analysis results.
Oliver Lyttleton, Alexander Wright, +2 authors, Paul Lewis.
J Pathol Inform, 2011 May 17; 2. PMID: 21572505    Free PMC article.
Toponostics of invasive ductal breast carcinoma: combination of spatial protein expression imaging and quantitative proteome signature analysis.
Claudia Röwer, Björn Ziems, +6 authors, Michael O Glocker.
Int J Clin Exp Pathol, 2011 Jul 09; 4(5). PMID: 21738817    Free PMC article.
Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
Patrick C O Leary, Sarah A Penny, +12 authors, William M Gallagher.
BMC Cancer, 2013 Apr 04; 13. PMID: 23547718    Free PMC article.
Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy.
Lynn T Dengel, Kimberly J Van Zee, +12 authors, Monica Morrow.
Ann Surg Oncol, 2013 Aug 27; 21(1). PMID: 23975314    Free PMC article.
The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.
Arthur Adams, Aram S A van Brussel, +4 authors, Sjoerd G Elias.
BMC Cancer, 2013 Nov 12; 13. PMID: 24206539    Free PMC article.
Systematic Review.
Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
Feng-yan Li, San-gang Wu, +5 authors, Zhen-yu He.
PLoS One, 2014 Feb 06; 9(2). PMID: 24498305    Free PMC article.
Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract.
J Douglas, A Sharp, +6 authors, S J Crabb.
Br J Cancer, 2014 Feb 22; 110(7). PMID: 24556622    Free PMC article.
Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.
Alicia D Powers, Sean P Palecek.
J Healthc Eng, 2012 Dec 01; 3(4). PMID: 25147725    Free PMC article.
Transcriptome sequencing uncovers a three-long noncoding RNA signature in predicting breast cancer survival.
Wenna Guo, Qiang Wang, +6 authors, Liucun Zhu.
Sci Rep, 2016 Jun 25; 6. PMID: 27338266    Free PMC article.
Identification of a four-long non-coding RNA signature in predicting breast cancer survival.
Mingjie Zhu, Qing Lv, +3 authors, Junqiang Wu.
Oncol Lett, 2020 Jan 04; 19(1). PMID: 31897133    Free PMC article.
Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma.
Lijuan Li, Nan Wu, +3 authors, Juntian Liu.
Cancer Biol Med, 2019 May 24; 16(1). PMID: 31119054    Free PMC article.